A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 3

Conditions: Obesity

Treatments: Drug: MK0557

Study type: Interventional

Funder types: Industry

Identifiers

NCT00092859

0557-011

2004_030

MK0557-011

Details and patient eligibility

About

This is a 2-year study to assess the safety, tolerability, and efficacy of an investigational drug in obese patients.

Enrollment: 1,500 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Obese men and nonpregnant women at least 18 years of age with a specific body mass index (height and weight ratio) required by the study

Exclusion criteria

• Patients with uncontrolled high blood pressure and/or diabetes mellitus (high blood sugar)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind